Cancer’s Worst Nightmare: How Biochemistry is Arming the Body to Fight Back

Imagine if your body had its own squad of highly trained assassins designed to precisely hunt down its prey—cancer cells. No more indiscriminate bombing of the body with chemotherapy, no more harming healthy cells as collateral damage. This may sound like science fiction, but thanks to breakthroughs in biochemistry, it is becoming a reality. Revolutionary new cancer treatments, such as monoclonal antibodies and CAR-T cell therapy, are turning these scientific fantasies into powerful medical tools.

Monoclonal antibodies are laboratory-designed proteins programmed to recognise and attack specific antigens on cancer cells. Often, cancer cells grow uncontrollably because the body inadvertently signals them to multiply. Monoclonal antibodies work by blocking these signals, slowing down or even halting the uncontrolled proliferation of cancer cells. A prominent example is Herceptin, a monoclonal antibody engineered to target HER2 receptors in breast cancer.

Cancer cells are notoriously skilled at evading detection by the immune system. They often camouflage themselves as healthy cells, effectively tricking the body into ignoring them. However, monoclonal antibodies act as precise locators, detecting these disguised cancer cells and triggering an immune response that leads to their destruction. In addition to signal-blocking and detection, some monoclonal antibodies act as Trojan horses, delivering chemotherapy or radioactive isotopes directly to cancer cells and eliminating them from within.

Furthermore, cancer cells often exploit immune checkpoints, molecular “brakes” that prevent the immune system from launching full-scale attacks. By targeting these checkpoints, monoclonal antibodies can release the brakes, allowing the immune system to aggressively combat cancer cells.

RHEA HIREMATH

While monoclonal antibodies are impressive, CAR-T cell therapy takes the battle against cancer to another level. Instead of merely injecting a drug, this treatment involves genetically reprogramming a patient's T cells to hunt down and destroy cancer cells with remarkable precision. The process begins with extracting T cells from a patient's blood and sending them to a lab where scientists insert a specially designed receptor, known as a Chimeric Antigen Receptor (CAR). This receptor enables the modified T cells to recognise cancer-specific antigens.

The modified T cells multiply rapidly in the lab, forming a powerful army of cancer-fighting cells. When infused back into the patient's bloodstream, these enhanced cells patrol the body, seeking out cancer cells with their newly acquired receptors. Upon locating their target, CAR-T cells initiate a devastating attack by releasing chemicals like perforin and granzymes that puncture cancer cell membranes, triggering their destruction. Simultaneously, they release cytokines, signaling the rest of the immune system to join the fight.

Cancer remains one of humanity's greatest challenges, but treatments like monoclonal antibodies and CAR-T cell therapy are revolutionising the medical field. They stand as testaments to the dedication and perseverance of scientists committed to finding effective treatments for this devastating disease. By understanding the biochemistry underlying these advancements, we move closer to transforming cancer into a manageable or even curable condition. The future of oncology is bright, and perhaps one day, the triumphant sound of patients celebrating their victory over cancer will become a commonplace occurrence.

RHEA HIREMATH

CITATIONS

BREASTCANCER.ORG. “Herceptin.” Www.breastcancer.org, 2024, www.breastcancer.org/treatment/targeted-therapy/herceptin.

Scott, Andrew M., et al. “Antibody Therapy of Cancer.” Nature Reviews Cancer, vol. 12, no. 4, 22 Mar. 2012, pp. 278–287, www.nature.com/articles/nrc3236, https://doi.org/10.1038/nrc3236.

National Cancer Institute. “CAR T Cells: Engineering Immune Cells to Treat Cancer.” National Cancer Institute, Cancer.gov, 10 Mar. 2022, www.cancer.gov/about-cancer/treatment/research/car-t-cells.

American Cancer Society. “CAR T-Cell Therapy and Its Side Effects.” Www.cancer.org, American Cancer Society, 11 Nov. 2024, www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html.